MedTrace Logo

A Study of ILB2109 in Patients With Advanced Solid Malignancies

NCT05278546 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-11-12

No results posted yet for this study

Summary

This is a multicenter, open-label, phase Ia study to evaluate the safety, tolerability and preliminary efficacy of ILB2109, a A2a receptor antagonist, in patients with locally advanced or metastatic solid malignancies.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

ILB2109

ILB2109 tablets by mouth once per day at dosages prespecified by the protocol. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Sponsors & Collaborators

  • Shanghai East Hospital

    collaborator OTHER

  • Shandong Cancer Hospital and Institute

    collaborator OTHER

  • Innolake Biopharm

    lead INDUSTRY

Principal Investigators

  • Jin Li, M.D. · Shanghai East Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-11
Primary Completion
2024-12-31
Completion
2025-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05278546 on ClinicalTrials.gov